LLY - Eli Lilly/Incyte announce peer-reviewed publication of Baricitinib/remdesivir trial data

Eli Lilly and Company (LLY) and Incyte (INCY) announce that the New England Journal of Medicine has published peer-reviewed results of the Phase 3 trial for baricitinib with remdesivir in hospitalized patients with COVID-19. The results support the emergency use authorization issued for the therapy by the FDA last month for adults and pediatric patients requiring supplemental oxygen.The ACTT-2 study was a double-blind, placebo-controlled trial sponsored by the National Institute of Allergy and Infectious Diseases.Andre Kalil, M.D., a principal investigator of the ACTT studies and the lead study author of the ACTT-2 New England Journal of Medicine manuscript, says "Results of this study demonstrated baricitinib in combination with remdesivir provided a faster median recovery time and reduced progression to ventilation or death compared to remdesivir alone in hospitalized COVID-19 patients on oxygen."Baricitinib, discovered by Incyte and licensed to Lilly, is an oral JAK inhibitor, approved for adults with moderate to severe rheumatoid arthritis in

For further details see:

Eli Lilly/Incyte announce peer-reviewed publication of Baricitinib/remdesivir trial data